Introduction: Recombinant human growth
INTRODUCTION
Growth hormone deficiency (GHD), which occurs when the pituitary gland produces insufficient growth hormone (GH) for adequate growth and development, can arise from a plethora of pathologies, although the cause in individual patients often remains obscure. 
Recombinant human GH (rhGH, somatropin)
stimulates production of insulin-like growth factor (IGF-1), which increases bone growth, muscle strength, and cardiac output, and enhances expression of IGF binding proteins (IGFBP-3). 2 However, growth response to GH treatment varies, even in a relatively homogeneous group of patients with defined inclusion-exclusion criteria, and with the same dose of GH used. 3 There are various possible reasons for this difference in growth response between patients but, at least in individual patients, it remains obscure. As a result, each treated group of children can be arbitrarily subdivided into poor, average, and good responders dependent upon growth response.
Nevertheless, the growth response during the first 6-12 months of treatment is predictive for further growth, 4 and treatment with rhGH improves final height; normalizes pubertal, sexual, and reproductive maturation; attenuates metabolic and cardiovascular risk factors; and facilitates adult psychosocial development. 5 Originally, therapeutic GH was extracted from cadaveric pituitary glands. However, by 1985, rhGH had replaced pituitary sources.
More recently, rhGH preparations GH biosimilars have been developed. The term "biosimilar" mainly defines a drug approval procedure, and does not suggest that complex biopharmaceuticals deriving from the same substance are entirely identical. 6 Indeed, the scientific and legal viability of biosimilars remains a topic of constant interest. 7 Descriptive statistics are provided as means ± SD or 95% CI. Figure 1 . Design of AQ study, Lyo study, and Spanish study. Omn=Omnitrope. population in the three studies, which are broadly similar despite some minor differences in the age and gender profiles. In the AQ study, one patient was excluded due to noncompliance during the first month, and another at month 15, also for noncompliance.
RESULTS

Demographics
Efficacy
Comparison of the (Standardized) Growth Development Between Switched and Nonswitched Patients
The curves for the development of height AQ study* Lyo study Spanish study Caucasian patients, n (%) 44 (100) § 51 (100) 69 (99) Patients with primary insufficiency of GH secretion, n (%) 44 (100) § 51 (100) 68 (97) Patients with secondary insufficiency of GH secretion, n (%) 0 (0) 0 (0) 2 (3) Table 1 . Summary of demographic and baseline characteristics of the intent-to-treat population in the AQ, Lyo, and Spanish studies.
*Group B of AQ study. †Ferrández Longas reference. 15 ‡Prader et al reference. 16 §One patient excluded for noncompliance at month 1. GH=growth hormone; SDS=SD score. Concentrations of IGF-I and IGFBP-3 rose during treatment with rhGH (Table 4) in all three studies, and the trend appeared to be comparable between studies.
Model-Based Analysis
A log-function model fitted growth data observed during 9 months of treatment with Genotropin.
Based on this model, the height up to month 18 was predicted and compared to the corresponding observed data. Table 2 . Comparison of differences in height SD score from baseline between the AQ, Lyo, and Spanish studies.
*Group B of AQ study. rhGH=recombinant human growth hormone. Number of patients varies depending on the available data at each visit.
Safety
All regimens were well tolerated, with few children experiencing ADRs (Table 5 ).
For example, in the Spanish study, only 10 of the 69 children experienced an ADR at any time during the 5-year follow-up. During the first 9 months, only five patients were affected by ADRs, and in the second 9-month period only three patients were affected. Only one patient was affected in both study periods.
In general, more ADRs were observed during the first than the second 9-month period of treatment, whether the patients were switched from Genotropin to Omnitrope liquid or stayed continuously on the same treatment (Table 5) .
Immunogenicity
Immunogenicity was uncommon in the groups included in this analysis. Table 3 . Comparison of differences in height velocity SD score from baseline between the AQ, Lyo, and Spanish studies.
presence of anti-GH antibodies in more than one test during the first 9 months of treatment with Omnitrope liquid could be detected in only one patient (Table 6 ).
After the 18-month period, another case of possible immunogenicity was detected, but this was of very short duration.
Similarly, no patient in the Lyo study In the Spanish study, two children showed sustained positive antibody results for at least 
DISCUSSION
The present study confirms what has already been established in the phase 3 Omnitrope trial, 10, 11 in that there is no difference in the efficacy or safety of patients switched from Genotropin to Omnitrope compared to patients receiving Omnitrope throughout the treatment period.
The authors' analysis has certain limitations. Finally, despite the potentially devastating consequences on height and other outcomes, poor adherence is relatively common among patients receiving rhGH. Indeed, some studies suggest that nonadherence rates are between 36%-49%. 20 In the AQ study, there was no examination addressing whether adherence rates differed before and after the switch. However, the very similar efficacy rates and the absence of an a priori reason to suspect pharmacodynamic differences between the rhGH preparations suggest that adherence rates were similar and thus, the groups are comparable.
Receiving market authorisation under the new regulatory biosimilar pathway r e q u i r e s t h e i m p l e m e n t a t i o n o f a n extensive comparability exercise with an established, authorized product. Thus, in the AQ phase 3 study, Omnitrope
(AQ group A) demonstrated comparability regarding efficacy and safety profile with Genotropin (AQ group B -switched group). 10, 11 This indicates that Genotropin and Omnitrope are equally effective, a suggestion confirmed by the lack of significant difference in the biochemical surrogate markers IGF-I and IGFBP-3 (Table 4) . Furthermore, the projected final height was 160.0 cm in girls and 172.5 Table 6 . Incidence of anti-growth hormone (GH) antibodies* during the first 18 months of treatment and overall.
*Presence of an anti-GH antibody is defined by at least two consecutive positive test results. †Group B of AQ study. were comparable in the AQ and Lyo studies.
The difference between the first and second 9 months was more marked for the Spanish study, although these data require cautious interpretation due to the small incidences. and source are credited.
